Wedbush Reaffirms Neutral Rating for Keros Therapeutics (NASDAQ:KROS)
Wedbush reissued their neutral rating on shares of Keros Therapeutics (NASDAQ:KROS – Free Report) in a report released on Friday,Benzinga reports. The brokerage currently has a $15.00 price target on the stock. Several other brokerages have also recently weighed in on KROS. Scotiabank dropped their price objective on Keros Therapeutics from $41.00 to $26.00 and […]
Wedbush reissued their neutral rating on shares of Keros Therapeutics (NASDAQ:KROS – Free Report) in a report released on Friday,Benzinga reports. The brokerage currently has a $15.00 price target on the stock. Several other brokerages have also recently weighed in on KROS. Scotiabank dropped their price objective on Keros Therapeutics from $41.00 to $26.00 and […]
